Lite Strategy (LITS) investor relations material

Executive summary

• Shifted strategic focus from oncology drug development to a dual strategy: digital asset treasury (Litecoin) and pre-clinical R&D in nononcology indications.

• Deployed $100M PIPE proceeds into Litecoin (LTC) as a primary reserve asset, launching the Litecoin Treasury Strategy in August 2025.

• Launched active treasury management by deploying covered call options on Litecoin holdings, generating $600,000 in gross premiums in the quarter.

• Initiated a $25M share repurchase program in October 2025, funded by treasury operations, repurchasing 137,541 shares at $1.47 average price by December 2025.

• Discontinued clinical development of voruciclib in oncology and ceased global development of zandelisib; now exploring out-licensing and sale opportunities.

Financial highlights

• Net loss of $30.8M for the quarter ended December 31, 2025, compared to $2.7M in the prior year quarter.

• Net loss of $34.4M for the six months ended December 31, 2025, versus $10.7M for the same period in 2024.

• Operating expenses rose to $29.9M for the quarter, mainly due to a $26.5M loss from change in fair value of digital assets.

• Generated $600,000 in cash from covered call options on LTC during the quarter.

• Cash and cash equivalents at $8.8M and digital assets at $64.0M as of December 31, 2025.

Outlook and guidance

• Sufficient liquidity (cash and digital assets) to fund operations for at least the next 12 months.

• Future capital requirements depend on the scope of the Litecoin Treasury Strategy and ongoing R&D activities.

• Plans to continue selective treasury strategies and execute the share repurchase program in the second half of fiscal 2026.

• Evaluating potential strategic investments or partnerships to expand operations and increase stockholder value.